Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter T. Yamaguchi
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors T. Yamaguchi1, S. Fushida2, T. Ohta2
  • 1Department of Gastroenterologic Surgery, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, /
  • 2Kanazawa University Hospital, Kanazawa, Japan, /


Tumor-associated macrophages of the M2 phenotype promote tumor proliferation and are associated with a poor prognosis in patients with various malignancies. We previously reported that large numbers of M2 macrophages have been found in the peritoneal cavity of gastric cancer patients with peritoneal dissemination. As M2 macrophages in the peritoneal cavity contribute to tumor progression, they are considered promising targets in patients who have gastric tumors with peritoneal dissemination. Paclitaxel (PTX) is an antineoplastic agent derived from the bark of the Pacific yew. Low dose PTX was shown to block tumor-induced polarization of conventional dendritic cells (DCs) into immunosuppressive regulatory DCs. However, it has not yet been determined whether PTX can modulate TAMs of the M2 phenotype. This study assessed whether PTX suppresses M2 macrophages, by acting as a Toll-like receptor 4 (TLR4) agonist.